Wang Ken, Parrott Neil John, Lavé Thierry
Pharma Early Research and Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
Product Development, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
Drug Discov Today. 2025 Mar;30(3):104322. doi: 10.1016/j.drudis.2025.104322. Epub 2025 Mar 1.
The adoption of virtual patients promises to revolutionize pharmaceutical R&D and health care through more patient-centric approaches and is driven by integrating innovations in computational approaches, AI, and advanced in vitro human model systems. Virtual patients can create the conditions for faster and more predictive R&D, affecting all drivers of R&D productivity. Virtual patients enable personalized health care, ensuring precise drug dosing and scheduling to maximize efficacy and minimize adverse effects. Numerous concrete examples demonstrate the transformative potential of virtual patients in real-world scenarios, showcasing significant improvements in drug development and clinical outcomes. Despite challenges in data variability, regulatory compliance, and data privacy, virtual patients hold immense potential to transform R&D and clinical practices, driving a new era of personalized and efficient R&D and health care.
采用虚拟患者有望通过更以患者为中心的方法彻底改变药物研发和医疗保健,其驱动力是整合计算方法、人工智能和先进的体外人体模型系统方面的创新。虚拟患者可以为更快、更具预测性的研发创造条件,影响研发生产力的所有驱动因素。虚拟患者能够实现个性化医疗保健,确保精确的药物剂量和给药时间安排,以最大限度地提高疗效并减少不良反应。众多具体实例证明了虚拟患者在现实场景中的变革潜力,展示了药物开发和临床结果的显著改善。尽管在数据可变性、法规合规性和数据隐私方面存在挑战,但虚拟患者在改变研发和临床实践方面具有巨大潜力,推动个性化和高效研发及医疗保健的新时代。